» Articles » PMID: 10721633

Determination of Intracranial Tumor Volumes in a Rodent Brain Using Magnetic Resonance Imaging, Evans Blue, and Histology: a Comparative Study

Overview
Date 2000 Mar 18
PMID 10721633
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The measurement of tumor volumes is a practical and objective method of assessing the efficacy of a therapeutic agent. However, the relative accuracy of different methods of assessing tumor volume has been unclear. Using T1-weighted, gadolinium-enhanced magnetic resonance Imaging (T1-MRI), Evans Blue infusion and histology we measured intracranial tumor volumes in a rodent brain tumor model (RT2) at days 10, 16 and 18 after implantation of cells in the caudate putamen. There is a good correlation between tumor volumes comparing T1-MRI and Evans Blue (r2 = 0.99), T1-MRI and Histology (r2 = 0.98) and histology and Evans Blue (r2 = 0.93). Each of these methods is reliable in estimating tumor volumes in laboratory animals. There was significant uptake of gadolinium and Evans Blue in the tumor suggesting a wide disruption of the blood-brain barrier.

Citing Articles

CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.

Lin Y, Chu Y, Liao W, Chen C, Hsiao W, Ho Y Am J Cancer Res. 2023; 13(7):2998-3012.

PMID: 37559985 PMC: 10408464.


The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens.

Mahajan S, Schmidt M, Schumann U Cancers (Basel). 2023; 15(7).

PMID: 37046685 PMC: 10093409. DOI: 10.3390/cancers15072024.


Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery.

Luo H, Shusta E Pharmaceutics. 2020; 12(11).

PMID: 33198244 PMC: 7697580. DOI: 10.3390/pharmaceutics12111085.


Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging.

Geisler J, Spehar J, Steck S, Bratasz A, Shakya R, Powell K J Vis Exp. 2020; (160).

PMID: 32568247 PMC: 8787807. DOI: 10.3791/61272.


HO-1 protects the nerves of rats with cerebral hemorrhage by regulating the PI3K/AKT signaling pathway.

Zhao Q, Qu R, Teng L, Yin C, Yuan Y Neuropsychiatr Dis Treat. 2019; 15:1459-1468.

PMID: 31239681 PMC: 6551621. DOI: 10.2147/NDT.S197030.